- Boxed warning added to Plavix label regarding possible reduced efficacy in certain patients
- FDA approves five-day dosing regimen of Eisai's Dacogen for MDS
- FDA approves Watson's six-month Trelstar formulation for palliative treatment of advanced prostate cancer
- Abbott submits sNDA for new formulation of Lupron Depot in advanced prostate cancer
- FDA grants 510(k) clearance to Fenwal to market Amicus blood cell separator for platelet-related use
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
Home :: Rheumatology :: Rheumatology Conferences
ACR 2007 Scientific Meeting
November 6-11, 2007 Boston, MA- Etanercept provides sustained efficacy, improved patient-reported outcomes in AS
- Targeting the IL-6 cytokine pathway presents exciting opportunities in variety of disease states, experts report
- Rituximab efficacious in patients with inadequate response to TNF inhibitors in repeated courses
- Treatment expectations with TNF inhibitors
- Adalimumab improves peripheral arthritis, enthesitis, axial signs, symptoms of AS in patients with long-standing disease treated in real-life practice, researchers report
EULAR 2007 Annual Congress
June 13-16, 2007 Barcelona, Spain- Biologics represent useful treatment for PsA; other therapies, approaches require more study
- Repair of joint erosions in patients with RA occurs primarily in joints with no swelling, improvement in swelling, researchers report
- Adalimumab safe, effective in anti-TNF-pretreated patients with PsA, study data show
- Certolizumab pegol improves signs, symptoms of RA among patients with insufficient response to methotrexate, study data show
- Anti-TNF agents may slow, protect against RA-related joint destruction, disability, work loss
- Adalimumab improves peripheral arthritis, enthesitis, axial signs, symptoms of AS in patients with long-standing disease treated in real-life practice, researchers report
- Infliximab infusion may increase risk of ventricular arrhythmias in patients with RA, data suggest
- Adalimumab improves symptoms, patient-reported outcomes in patients with psoriasis, PsA, data show
- Oral JAK-3 inhibitor plus methotrexate efficacious, safe in RA
- Golimumab improves signs, symptoms, physical function among patients with AS, study data show
- Infliximab infusion may increase risk of ventricular arrhythmias in patients with RA, data suggest
- Canadian Rheumatology Association, Spondyloarthritis Research Consortium of Canada publish recommendations for treatment of SpA
- Denosumab, certolizumab show promise as potential treatments in RA
- Oral JAK-3 inhibitor plus methotrexate efficacious, safe in RA
- Increase in risk of heart failure slight among younger anti-TNF-treated patients with RA, Crohn's disease
